Heron Therapeutics Inc vs Wynn Resorts, Limited — how do they compare? Heron Therapeutics Inc trades at $0.35 (market cap $61.47M), while Wynn Resorts, Limited trades at $103.72 (market cap $10.79B). The key difference: Wynn Resorts, Limited is far larger — about 175.5× Heron Therapeutics Inc's market cap, and Wynn Resorts, Limited pays a 0.95% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | WYNN | |
|---|---|---|
Market Cap | $61.47M | $10.79B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.49 | $133.34 |
52-Week Low | $0.32 | $94.37 |
Enterprise Value | $168.21M | $21.03B |
Dividend Yield | — | 0.95% |
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3507, up 6.21% in the last 24 hours, but technical indicators signal a bearish trend overall. The company reported Q2 2026 revenue of $37.7 million, missing estimates, with a net loss per share of $0.03. Despite a high gross profit margin of 70.07%, negative net income and cash flow from operations highlight financial strain. Analyst consensus remains strongly bullish with 94.74% buy ratings, but recent news includes a Zacks Strong Sell designation on July 15, 2026.
The outlook is mixed: strong analyst support contrasts with weak earnings and bearish technicals. Investment opportunity lies in potential turnaround if revenue growth accelerates, but risks include persistent losses, competitive pressures, and reliance on financing activities. The stock faces significant downside if operational performance does not improve.
Wynn Resorts (WYNN) trades at $104.59, up 2.04% today, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations, driven by Macau performance, though U.S. margins face pressure. The company maintains solid revenue growth but carries high debt levels, with net cash flow negative due to significant capital expenditures for expansion projects like Wynn Al Marjan.
The outlook is cautiously optimistic, with a consensus price target of $133 offering ~27% upside. Key opportunities include Macau recovery and new project growth, while risks involve high leverage, rising capex, and regional economic sensitivity. Investors should weigh strong institutional support against execution risks in upcoming expansions.
Trailing returns across standard periods
Latest headlines on both assets
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →